PeptidePicker
Home/Peptides/Desmopressin
ClinicalFDA Approved

Desmopressin

Also known as: DDAVP · Minirin

A synthetic vasopressin analog with enhanced antidiuretic potency and no vasoconstrictive effects. Clinical standard for diabetes insipidus and hemophilia A.

Dr. Sarah Mitchell

Reviewed by Dr. Sarah Mitchell, PharmD, BCPS

Lead Researcher · 12+ years in peptide therapeutics

Half-Life

~3 hours

Typical Dose

0.1–0.4 mg oral or 10–40 mcg intranasal

Administration

Oral, intranasal, or IV

Mechanism of Action

Selectively activates V2 vasopressin receptors in renal collecting ducts to increase water reabsorption and release von Willebrand factor stores.

Key Research Areas

clinicalFDA approveddiabetes insipidushemophilia

Frequently Asked Questions

What is Desmopressin?
A synthetic vasopressin analog with enhanced antidiuretic potency and no vasoconstrictive effects. Clinical standard for diabetes insipidus and hemophilia A.
How does Desmopressin work?
Selectively activates V2 vasopressin receptors in renal collecting ducts to increase water reabsorption and release von Willebrand factor stores.
What is the recommended dosage for Desmopressin?
The typical research dosage is 0.1–0.4 mg oral or 10–40 mcg intranasal, administered via Oral, intranasal, or IV. Dosage protocols vary by study and should be determined by a qualified healthcare professional.
What is the half-life of Desmopressin?
The half-life of Desmopressin is approximately ~3 hours. This affects dosing frequency and timing in research protocols.
Is Desmopressin FDA approved?
Yes, Desmopressin is FDA approved for specific medical indications. Consult your physician for proper medical guidance.

Research Disclaimer

The information provided about Desmopressin is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before starting any peptide protocol. Products discussed have not been evaluated by the FDA unless explicitly noted.

Related Peptides in Clinical